A French Observational Study of Indocyanine Green for Patients With Breast Cancer Having a Sentinel Lymph Node Biopsy.

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

June 6, 2023

Primary Completion Date

November 6, 2023

Study Completion Date

December 19, 2023

Conditions
Breast Cancer
Interventions
PROCEDURE

Sentinel lymph node identification

Intervention description: Intraoperative identification of sentinel lymph node

DRUG

indocyanine green

Intervention description: indocyanine green (5 to 10 mg \[ie, 2 to 4 mL of a 2.5 mg/mL solution\]) administered by periareolar or peritumoural route

DRUG

methylene blue

1%), 2-5 mL administered by periareolar or peritumoural route

DRUG

Technetium (99mTc)

(99mTc, 0.2 - 0.4 mCi in 0.4 mL administered by periareolar or peritumoural route

Trial Locations (6)

33000

Institut Bergonié, Bordeaux

54500

Institut de Cancérologie de Lorraine, Vandœuvre-lès-Nancy

59000

CHU de Lille, Lille

74370

CH Annecy-Genevois, Annecy

75015

Hôpital Européen Georges-Pompidou Paris, Paris

42100 France

CHU de Saint-Etienne, Saint-Étienne-de-Montluc

Sponsors
All Listed Sponsors
collaborator

Iqvia Pty Ltd

INDUSTRY

lead

BTG International Inc.

OTHER